BiotechTube
Nanovalent Pharmaceuticals

Nanovalent Pharmaceuticals

Cambridge, United States· Est.
nanovalent.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Nanovalent Pharmaceuticals is a preclinical-stage biotech leveraging its unique Hybrid Polymerized Liposomal Nanoparticle (HPLN) platform to create next-generation targeted nanotherapeutics, termed nADC/TNS. The company's lead candidate, NV103/NV105, is approaching IND status and targets CD99-expressing tumors such as glioblastoma, Ewing sarcoma, pancreatic, and ovarian cancers. Its platform aims to overcome limitations of traditional ADCs by enabling higher drug payloads, enhanced tumor targeting, and reduced systemic toxicity, with potential applications beyond oncology in neurological diseases due to blood-brain barrier penetration.

OncologyNeurological Diseases

Technology Platform

Hybrid Polymerized Liposomal Nanoparticle (HPLN) platform used to create nano-ADC-like Targeted Nanospheres (nADC/TNS). The technology involves drug-loaded nanoparticles decorated with multiple monoclonal antibodies for polyvalent targeting, enabling high drug payloads, enhanced tumor specificity, and blood-brain barrier penetration.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The platform's ability to deliver higher drug payloads with greater specificity than traditional ADCs addresses a core limitation in targeted cancer therapy, offering a potential best-in-class profile in high-need oncology segments.
The technology's blood-brain barrier penetration creates a significant lateral opportunity to treat glioblastoma and other neurological disorders, a market with very few effective targeted options.

Risk Factors

The novel nanoparticle technology is unproven in humans, carrying high scientific risk that preclinical advantages may not translate to clinical safety or efficacy.
As a pre-revenue, private company, it faces substantial funding risk to advance its lead candidate into costly clinical trials.

Competitive Landscape

Nanovalent competes in the crowded and rapidly evolving field of antibody-drug conjugates (ADCs) and targeted nanotherapies, against large pharma and well-funded biotechs. Its success depends on demonstrating clear superiority over existing ADCs in terms of therapeutic index, payload capacity, or access to difficult-to-treat tissues like the brain.

More companies in Drug Delivery & Formulation →More companies in United States →